Company Overview
Ambalal Sarabhai Enterprises Ltd (BSE -ticker AMBL -symbol 500009) is an Indian firm involved in electronics and pharmaceuticals. Its operations include finished dosage form, active pharmaceutical ingredients (APIs), oncology, infertility, uro-gynaecology, veterinary products, diagnostics and some electronics instrumentation subsidiaries.
The company was established in 1977 (incorporated in 1978 according to some sources) and it runs several subsidiaries, such as Asence Pharma, Systronics, Synbiotics, Sarabhai Chemicals, and so forth.
It has its headquarters in Ahmedabad.
Lasting Stock Price Snapshot.
The table below shows the latest figures of Ambalal Sarabhai Enterprises Ltd:
Metric Value
Recent closing / quoted share price ~ [?] 31.50 – [?] 32.50 per share.
52-week high [?] [?] 68.00
52-week low [?] [?] 30.00
Market Cap ~ [?] 241-[?] 244 crore
P/E Ratio (TTM) Around 19.1-19.2x
Price-to-Book Value ~ 1.7-1.8x
Dividend Yield 0%- no dividend has been declared recently.
Recent Performance & Trends
The stock has been falling approximately 50-52 percent of its 52-week high within the past year.
The stock has been moving within a fairly narrow range in the recent past, with the stock being nearer to the lower part of the 52 week limits around [?]. 30.
Liquidity: Volume is modest. Low to medium volume trading days are present.
Financial Health & Ratios
Some of the key fundamentals:
Revenue (TTM / last fiscal year): About [?] 1,900-2,000 crore.
Net Income: Over the past few years, the profitability has been on the downward trend; the most recent net income is smaller, indicating the pressures on the margin.
ROE: Moderate with a range of between 6-8 per cent in the recent years.
Promoter holding and public: and the majority of the shares are held by promoters (31-32%), with the remainder by public shareholders.
Various portfolio in pharmaceuticals, diagnostics, electronics and APIs.
Existence in the field of specialization (oncology, infertility, etc.).
Exporting and international registration subsidiaries.
Challenges
The share has experienced significant drops since it hit its peak, and this could be an indication of market apprehensions regarding growth, margins or rivalry.
Recently no dividends which could make it less appealing to income seeking investors.
Subpar ROE relative to high growth pharma peers.
Price is not very far above 52-week lows, or it means that there is not much upside in the recent past or perhaps most of the concerns have already been factored in.
Outlook
There is potential of recovery in case the company can enhance the margins, perhaps by increasing the margin APIs or diagnostics and electronics.
The regulatory, competition, cost of raw materials and global trade environments will be significant.
It is important to monitor new product launches, approvals (particularly oncology and APIs) and the performance of its electronics instrumentation business.
FAQ (Frequently Asked Questions)
Q1. What is the present share rate of Ambalal Sarabhai Enterprises Ltd?
A1. The value of the stock is approximately [?] 31.50-[?] 32.50 in mid-September 2025.
Q2. What are the high and low prices of 52 weeks?
A2. The 52 week high is [?] 68.00, and the 52 week low is [?] 30.00.
Q3. Where does the company stand with respect to market capitalization?
A3. Market cap is roughly [?] 240-[?] 250 crore.
Q4. What are its earnings, P/E ratio and other valuation measures?
A4. P/E (TTM) is ~ 19.1-19.2x. Price-to-book is around 1.7-1.8x. The recent years have a moderate ROE (~6-8%).
Q5. Does the firm pay dividends?
A5. Nothing has been paid out recently. Dividend yield is presently 0%.
Q6. How volatile is the stock?
A6. Quite unstable, as the decrease of [?] 68 to 30 in the past 52 weeks was steep. But the variation has decreased in the past few months.
Q7. What are the principal risks of the stock?
A7. These risks are competitive, regulatory (particularly with pharma) fluctuations, narrowing of margins, foreign exchange, and potential deceleration in the growth of electronics or diagnostics businesses.
Q8. Is the concentration of shareholding in the hands of promoters?
A8. Promoters have a share of approximately 31-32; the rest of the shares approximate 68-69 has been kept by the public/investors.
Q9. Where and what is the ticker?
A9. It has its listing on the Bombay Stock Exchange (BSE) with code 500009. The share symbol/ticker is either AMBL or in some platforms AMBLALSA.
Yahoo Finance
Conclusion
Ambalal Sarabhai Enterprises Ltd is a middle level company with diversified portfolio pharma + electronics. The stock has not been performing well in the past one year as it has significantly declined in its highs. Conversely, the current price can also provide a long-term investor opportunity in case the company could improve its financially poor areas, get regulatory approvals, and enhance margins.
As usual, to make investment decisions, one must supplement this summary with current financial reports, information about the company developments (product approvals, subsidiaries performance) and macroeconomic factors that impact pharmaceuticals and electronics.
